Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 13, 2019 16:05 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 10, 2019 21:05 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 09, 2019 16:18 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH
December 09, 2019 10:00 ET
|
Constellation Pharmaceuticals , Inc.
Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%)...
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610
December 02, 2019 11:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences
November 13, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
November 06, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...
Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH
October 10, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Company will hold investor event on December 9 at 12:30 PM CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical...
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors
October 01, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference
September 26, 2019 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...